Navigation Links
Pharmaceutical Marketing Done Right: Archi-Tech Systems Unveils Version of Proven Analytics Solution for Campaign Management
Date:7/10/2008

WEST TRENTON, N.J., July 10 /PRNewswire/ -- Archi-Tech Systems, a leading provider of pharmaceutical data analytics and reporting solutions, today announced DART(TM) PromoTrack, a new solution custom-designed to rapidly measure the impact of pharmaceutical marketing campaigns and prescriber promotions. Archi-Tech has tailored its proven DART technology to meet the specific needs of pharmaceutical marketers, seamlessly integrating disparate promotional campaign and Rx sales data to facilitate on-the-fly analytics and reporting. For the first time, marketers have endless configurations of critical data at their fingertips to better monitor advertising, sampling, educational seminars, and other promotional tools for compliance and effectiveness.

"Pharmaceutical marketers are challenged to run successful campaigns under tight budgets and intense regulatory scrutiny. But with mountains of data to sift through, they often cannot properly measure the results of their promotions to adapt their strategies accordingly," said Prashant Kohli, Vice President of Sales and Marketing for Archi-Tech. "DART PromoTrack provides faster, more accurate insight into specific campaigns to improve planning, streamline targeting, enhance messaging, ensure compliance -- and ultimately maximize marketing dollars spent."

Built on the proven DART solution, already widely used by the pharmaceutical industry for instant, in-depth analytics and reporting on sales, marketing, and managed care data, DART PromoTrack offers unmatched flexibility to analyze and report on any configuration of data across the full scope of prescriber metrics and activity. This brings together Rx, call/sample, demographic, campaign, promotional, and other detail in a single view that encompasses millions of physicians and multiple markets and specialties. Pharmaceutical marketing teams can run multi-dimensional searches in seconds, conduct ad-hoc analyses, and generate instant reports on a wide range of datasets and parameters, regardless of volume or complexity. This yields actionable information to more effectively track marketing initiatives, manage control group activity, monitor trends, review results against actual performance, and more.

About Archi-Tech

Archi-Tech Systems is a leading provider of solutions for instant analytics and powerful reporting for pharmaceutical sales, marketing, and managed care departments. Balancing deep data expertise with advanced technology solutions and a unique service model, Archi-Tech addresses the full scope of a company's data analysis and reporting needs, no matter how simple or complex. The company's solutions offer unmatched speed and compression for any type of data, from any source, regardless of volume or complexity. In addition, the Archi-Tech team offers more than 100 years of combined experience with industry leading data vendors, and direct pharmaceutical client service experience. This translates to a unique understanding of the data, and exactly how our clients need to use it. For more information, visit http://www.archi-tech.com.


'/>"/>
SOURCE Archi-Tech Systems
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pacira Pharmaceuticals, Inc. Adds Board Member and Key Senior Management
2. Par Pharmaceutical to Launch meclizine HCL Tablets
3. Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering
4. Lilly to Acquire SGX Pharmaceuticals
5. New MedPredict Report Highlights Trend Toward Early Diagnosis and Treatment of Rheumatoid Arthritis, Impact on Pharmaceutical Development
6. Pharmaceutical Institute, in Collaboration With Campbell Alliance, Releases Second Edition of Breakthrough Book on the Inner Workings of the Pharmaceutical Industry
7. Edison Pharmaceuticals Receives Commendation From the City of San Jose
8. Huifeng Bio-Pharmaceutical (HFGB) Information to Be Available Through Standard & Poors Market Access Program
9. Transcept Pharmaceuticals Appoints Key Senior Executives
10. Addrenex Pharmaceuticals Licenses New Compound to Sciele Pharma for the Treatment of Hypertension and Other Potential Indications
11. Peregrine Pharmaceuticals Awarded DTRA Contract Worth up to $44.4 Million to Develop Bavituximab for Viral Hemorrhagic Fevers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... Cumberland Foreside, Maine (PRWEB) , ... January 17, ... ... to announce the addition of Rheumatoid Factor (RF) to its VALIDATE® SP2 calibration ... and Rheumatoid Factor in a human serum base. Each VALIDATE® SP2 kit is ...
(Date:1/17/2017)... DIEGO , Jan. 17, 2017  An ... School of Medicine and St. Boniface Hospital Albrechtsen ... for peripheral neuropathy, an unmet health need affecting ... the Journal of Clinical Investigation, their results identify ... that prevent and reverse neuronal injury in animal ...
(Date:1/17/2017)... 2017   Pulmatrix, Inc . (NASDAQ: ... inhaled therapies to address serious pulmonary diseases, today announced ... the lungs of CF patients, PUR1900, has been designated ... U.S. Food & Drug Administration. Under ... the development of novel drugs against important pathogens, Pulmatrix ...
(Date:1/17/2017)...  Only nine percent of U.S. consumers believe pharmaceutical ... 16 percent believe health insurance companies do, according to ... of U.S. adults believe health care providers (such as ... hospitals (23%). "We are in the midst ... , vice president of reputation management and public affairs ...
Breaking Biology Technology:
(Date:12/15/2016)... , Dec. 14, 2016 "Increase in mobile ... market" The mobile biometrics market is expected to grow ... billion by 2022, at a CAGR of 29.3% between ... such as the growing demand for smart devices, government ... "Software component is expected to grow at ...
(Date:12/7/2016)... , December 7, 2016 According to a new market ... Software Tool (Facial Expression, Voice Recognition), Service, Application Area, End User, And Region ... to grow from USD 6.72 Billion in 2016 to USD 36.07 Billion by ... Continue Reading ... MarketsandMarkets ...
(Date:12/6/2016)... -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) (the "Company") ... million principal amount of its 1.414% senior unsecured notes due ... unsecured notes due 2026. The closing of ... to the satisfaction of customary closing conditions.  The notes will ... The Company intends to use the net proceeds from ...
Breaking Biology News(10 mins):